I am not focused on the 'past'. As I said, I drop in to see whats being talked about, see whats 'changed' and if it has any potential to lift something up.
Didn't say any insulin is 'better' than afrezza, even back then. But the developments that were approved helped 'neutralize' the benefit of afrezza. And don't ask me to name the developments cause that was hell, way back in 2014/15 timeframe. But they got all the market attention when they did get approved and it was part of that equation, thanks to the negative PR about 'lung cancer' (which was BS at the time) concern campaign, that said, market adoption isn't going to go well. And I remember monitoring the spreadsheet someone kept updating on a weekly basis, looking for revenue increasing for signs of market desire.
Ok, guess its time to go back to quiet mode.. but I do believe I recognize a couple of names that were 'in' back then..